The drug patent recognises a novel microfluidics device invented by the team of Pakistani researchers that will enable the monitoring of terminally ill patients being given therapeutic drugs or those undergoing treatment from sensitive drugs which require real time monitoring to prevent over-dose.
The United States Patent and Trademark Office (USPTO) has granted permision to a team of researchers from COMSATS University, Islamabad for a new technology they have developed. The team comprises Dr Madeeha Chaudry, Dr Malik Abdul Rehman, Prof Dr Raheel Qamar and Prof Dr Arshad Saleem Bhatti.
The patent recognises a novel microfluidics device invented by the team of researchers that will enable the monitoring of terminally ill patients.
This US patent is an outcome of research undertaken by Dr Chaudry for her PhD, which led to the creation of a novel device for real-time drug monitoring of patients using very small blood serum samples on the principle of a microchip assay.
The inter-disciplinary research was carried out jointly by the Department of Physics and the Department of Biosciences at COMSATS University, Islamabad.
The patent application incorporates data submitted as part of the Pakistani Patent Application No.339/2016 and will enable Pakistani researchers to commercialize their research in the United States.